EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Anti-Islet Autoantibodies in Type 1 Diabetes

Eiji Kawasaki iD

International Journal of Molecular Sciences · 11.06.2023 · 24 (12) · 10012

DOI: 10.3390/ijms241210012 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 11.06.2023. Verfasst von Eiji Kawasaki. Beteiligte Einrichtung: Diabetes Center, Shin-Koga Hospital, Kurume 830-8577, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Autoimmune Diseases. Die Arbeit wurde bisher 111-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anti-islet autoantibodies serve as key markers in immune-mediated type 1 diabetes (T1D) and slowly progressive T1D (SPIDDM), also known as latent autoimmune diabetes in adults (LADA). Autoantibodies to insulin (IAA), glutamic acid decarboxylase (GADA), tyrosine phosphatase-like protein IA-2 (IA-2A), and zinc transporter 8 (ZnT8A) are currently employed in the diagnosis, pathological analysis, and prediction of T1D. GADA can also be detected in non-diabetic patients with autoimmune diseases other than T1D and may not necessarily reflect insulitis. Conversely, IA-2A and ZnT8A serve as surrogate markers of pancreatic β-cell destruction. A combinatorial analysis of these four anti-islet autoantibodies demonstrated that 93–96% of acute-onset T1D and SPIDDM cases were diagnosed as immune-mediated T1D, while the majority of fulminant T1D cases were autoantibody-negative. Evaluating the epitopes and immunoglobulin subclasses of anti-islet autoantibodies help distinguish between diabetes-associated and non-diabetes-associated autoantibodies and is valuable for predicting future insulin deficiency in SPIDDM (LADA) patients. Additionally, GADA in T1D patients with autoimmune thyroid disease reveals the polyclonal expansion of autoantibody epitopes and immunoglobulin subclasses. Recent advancements in anti-islet autoantibody assays include nonradioactive fluid-phase assays and the simultaneous determination of multiple biochemically defined autoantibodies. Developing a high-throughput assay for detecting epitope-specific or immunoglobulin isotype-specific autoantibodies will facilitate a more accurate diagnosis and prediction of autoimmune disorders. The aim of this review is to summarize what is known about the clinical significance of anti-islet autoantibodies in the pathogenesis and diagnosis of T1D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Autoimmune DiseasesAdultHumansAutoantibodiesInsulinInsulin, Regular, HumanGlutamate Decarboxylase

Stichwörter der Autor:innen

enzyme-linked immunosorbent assayepitopeglutamic acid decarboxylaselatent-autoimmune diabetes in adultspredictiontype 1 diabetes

Substanzen

AutoantibodiesInsulinInsulin, Regular, HumanGlutamate Decarboxylase

Autor:innen und Institutionen

  • Diabetes Center, Shin-Koga Hospital, Kurume 830-8577, Japan.

ORCID-Profile: Eiji Kawasaki

Zitieren

APA

Kawasaki, E. (2023). Anti-Islet Autoantibodies in Type 1 Diabetes. International Journal of Molecular Sciences, 24(12), 10012. https://doi.org/10.3390/ijms241210012

Vancouver

Kawasaki E. Anti-Islet Autoantibodies in Type 1 Diabetes. International Journal of Molecular Sciences. 2023;24(12):10012. doi:10.3390/ijms241210012

BibTeX
@article{Kawasaki2023,
  author = {Kawasaki, Eiji},
  title = {Anti-Islet Autoantibodies in Type 1 Diabetes},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {12},
  pages = {10012},
  doi = {10.3390/ijms241210012}
}
Kostenlos starten →